Neuromuscular Disorders

The significance of glial cells in the pathophysiology of ALS 3:23
The significance of glial cells in the pathophysiology of ALS
Serge Przedborski • 16 Sep 2022
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD) 8:29
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD)
Christopher Morabito • 11 Apr 2022
Updates on peripheral autoimmune neurological conditions 2:44
Updates on peripheral autoimmune neurological conditions
Divyanshu Dubey • 12 Apr 2022
Diagnostic work up of autoimmune neurological conditions 3:13
Diagnostic work up of autoimmune neurological conditions
Divyanshu Dubey • 12 Apr 2022
Immunotherapy strategies for autoimmune disorders of the nervous system 1:43
Immunotherapy strategies for autoimmune disorders of the nervous system
Divyanshu Dubey • 12 Apr 2022
Phase II extension trial of CNM-Au8 in ALS 1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan • 4 Apr 2022
The pipeline of late-stage therapeutic options for patients with ALS 1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan • 4 Apr 2022
Future lines of research in synucleinopathies 1:23
Future lines of research in synucleinopathies
Elizabeth Coon • 1 Apr 2022
Using real-world data in SMA management 2:18
Using real-world data in SMA management
Anna Kostera-Pruszczyk • 25 Jun 2022
The diagnostic evaluation of hereditary and acquired neuromuscular diseases 0:48
The diagnostic evaluation of hereditary and acquired neuromuscular diseases
Anna Kostera-Pruszczyk • 27 Jun 2022
AOCs: future outlooks in other disease areas 1:46
AOCs: future outlooks in other disease areas
Arthur Levin • 6 Apr 2022
AOCs in neuromuscular disorders: Duchenne muscular dystrophy 4:11
AOCs in neuromuscular disorders: Duchenne muscular dystrophy
Arthur Levin • 6 Apr 2022
Optimization of myasthenia gravis management: knowledge gaps 3:24
Optimization of myasthenia gravis management: knowledge gaps
James F. Howard Jr. • 12 Apr 2022
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers 1:53
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers
Arthur Levin • 6 Apr 2022
AOC programs in development for DMD and myotonic dystrophy 4:27
AOC programs in development for DMD and myotonic dystrophy
Arthur Levin • 6 Apr 2022
Complement inhibitor therapy for myasthenia gravis: current and future outlooks 2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr. • 12 Apr 2022
The content of VJNeurology is intended for healthcare professionals